Gene: PPP1R13L

10848
IASPP|NKIP1|RAI|RAI4
protein phosphatase 1 regulatory subunit 13 like
protein-coding
19q13.32
Ensembl:ENSG00000104881 MIM:607463 Vega:OTTHUMG00000181784 UniprotKB:Q8WUF5
NC_000019.10
PubMed
0   ANCO-SNPs
ND
8   
NA (AD)  NA (ND)   (Frontal_Cortex)
2.757e-1 (AD)  6.406e-1 (ND)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg07924081chr19:45898892PPP1R13L2.600e-16Smoking27651444

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
GSDMD0.803
RGL30.793
TLN10.783
SYDE10.775
SIPA10.768
LAMB20.768
RRAS0.761
DOCK60.753
NOTCH10.75
MOB3C0.75

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
SMIM18-0.576
MARCH4-0.553
PPEF1-0.548
CRH-0.538
ABCC12-0.531
TPBGL-0.525
SLC1A6-0.523
ASB18-0.522
PTPRR-0.52
CDH8-0.516

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R13L mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R13L mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R13L mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R13L mRNA"27188386
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of PPP1R13L gene27153756
D016604Aflatoxin B1Aflatoxin B1 results in increased expression of PPP1R13L mRNA19770486
D001151ArsenicArsenic affects the methylation of PPP1R13L gene25304211
D001280AtrazineAtrazine results in increased expression of PPP1R13L mRNA22378314
C547126AZM551248AZM551248 results in decreased expression of PPP1R13L mRNA22323515
C006780bisphenol Abisphenol A results in increased expression of PPP1R13L mRNA25181051
D002104CadmiumCadmium results in increased expression of PPP1R13L mRNA24376830
D019327Copper SulfateCopper Sulfate results in increased expression of PPP1R13L mRNA19549813
D003375CoumestrolCoumestrol results in decreased expression of PPP1R13L mRNA19167446
D016572CyclosporineCyclosporine results in increased expression of PPP1R13L mRNA25562108
D003630DaunorubicinPPP1R13L results in decreased susceptibility to Daunorubicin19299014
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of PPP1R13L mRNA28628672
D003993Dibutyl PhthalateDibutyl Phthalate results in increased expression of PPP1R13L mRNA21266533
D002945CisplatinCisplatin results in increased phosphorylation of PPP1R13L protein22006019
D004147DioxinsDioxins affects the expression of PPP1R13L mRNA20463971
C118739entinostatentinostat results in increased expression of PPP1R13L mRNA27188386
D005047EtoposideEtoposide results in increased expression of and results in increased localization of PPP1R13L protein17570360
D005047EtoposideEtoposide results in increased expression of PPP1R13L mRNA17570360
D005047EtoposidePPP1R13L results in decreased susceptibility to Etoposide19299014
D006861Hydrogen PeroxideHydrogen Peroxide affects the expression of PPP1R13L mRNA20044591
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of PPP1R13L mRNA28628672
D007213IndomethacinIndomethacin results in decreased expression of PPP1R13L mRNA28201806
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin] results in decreased expression of PPP1R13L mRNA28628672
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of PPP1R13L mRNA24796395
C045463leflunomideleflunomide results in decreased expression of PPP1R13L mRNA28988120
C482199lipopolysaccharide, E coli O55-B5"lipopolysaccharide, E coli O55-B5 results in increased expression of PPP1R13L mRNA"24972896
C004925methylmercuric chloridemethylmercuric chloride results in increased expression of PPP1R13L mRNA23458150
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of PPP1R13L mRNA26011545
D009151Mustard GasMustard Gas results in increased phosphorylation of PPP1R13L protein19845377
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in increased expression of PPP1R13L mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in increased expression of PPP1R13L mRNA"25554681
D010100OxygenOxygen deficiency results in increased expression of PPP1R13L mRNA26516004
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R13L mRNA"27188386
C496932panobinostatpanobinostat results in increased expression of PPP1R13L mRNA26272509
D010416PentachlorophenolPentachlorophenol results in increased expression of PPP1R13L mRNA23892564
D010936Plant ExtractsPlant Extracts results in decreased expression of PPP1R13L mRNA23557933
D011794QuercetinQuercetin results in increased expression of PPP1R13L mRNA21632981
C009277sodium arsenatesodium arsenate results in increased expression of PPP1R13L mRNA23922661
D000952Antigens, Polyomavirus Transforming"Antigens, Polyomavirus Transforming results in increased expression of PPP1R13L mRNA"26680231
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of PPP1R13L mRNA21570461
D014212TretinoinTretinoin results in increased expression of PPP1R13L mRNA20530235
D014212TretinoinTretinoin results in increased expression of PPP1R13L mRNA23724009
C012589trichostatin Atrichostatin A results in increased expression of PPP1R13L mRNA24935251|2670570
D014520UrethaneUrethane results in increased expression of PPP1R13L mRNA28818685
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R13L mRNA"27188386
D014635Valproic AcidValproic Acid results in decreased expression of PPP1R13L mRNA29154799
D014635Valproic AcidValproic Acid results in increased expression of PPP1R13L mRNA23179753|2438349
D014635Valproic AcidValproic Acid results in increased methylation of PPP1R13L gene29154799
C025643vinclozolinvinclozolin results in decreased expression of PPP1R13L mRNA23034163

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0003714transcription corepressor activity-TAS10336463  
GO:0005515protein binding-IPI17906639  18275817  18985028  21513714  21998301  22321011  
23623661  24855949  26496610  27173435  28330616  
GO:0008134transcription factor binding-IEA-  
GO:0042802identical protein binding-IPI18275817  23623661  
GO:0045296cadherin binding-HDA25468996  
GO ID GO Term Qualifier Evidence PubMed
GO:0000122negative regulation of transcription by RNA polymerase II-IEA-  
GO:0003215cardiac right ventricle morphogenesis-IEA-  
GO:0003229ventricular cardiac muscle tissue development-IEA-  
GO:0006351transcription, DNA-templated-IEA-  
GO:0006915apoptotic process-IEA-  
GO:0009791post-embryonic development-IEA-  
GO:0031076embryonic camera-type eye development-IEA-  
GO:0035264multicellular organism growth-IEA-  
GO:0042633hair cycle-IEA-  
GO:0045597positive regulation of cell differentiation-IEA-  
GO:0048871multicellular organismal homeostasis-IEA-  
GO:0060048cardiac muscle contraction-IEA-  
GO:1901796regulation of signal transduction by p53 class mediator-TAS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-TAS10336463  
GO:0005654nucleoplasm-TAS-  
GO:0005829cytosol-IDA-  
GO:0030054cell junction-IDA-  
GO:0045171intercellular bridge-IDA-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-212436Generic Transcription PathwayTAS
R-HSA-3700989Transcriptional Regulation by TP53TAS
R-HSA-5633007Regulation of TP53 ActivityTAS
R-HSA-6804759Regulation of TP53 Activity through Association with Co-factorsTAS
R-HSA-73857RNA Polymerase II TranscriptionTAS
R-HSA-74160Gene expression (Transcription)TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
22335888A specific diplotype defined by PPP1R13L rs1970764, CD3EAP rs967591 and ERCC1 rs11615 and lung cancer risk in a Chinese population. (2012 Jun)Yin JLung Cancer
27183913Fine-mapping markers of lung cancer susceptibility in a sub-region of chromosome 19q13.3 among Chinese. (2016 Sep 20)Yin JOncotarget
26681190Genetic Polymorphisms in XRCC1, CD3EAP, PPP1R13L, XPB, XPC, and XPF and the Risk of Chronic Benzene Poisoning in a Chinese Occupational Population. (2015)Xue PPLoS One
29108262Association of PPP1R13L and CD3EAP polymorphisms with risk and survival of non-small cell lung cancer in Chinese non-smoking females. (2017 Oct 3)Feng XOncotarget
25917613NFKB1 common variants and PPP1R13L and CD3EAP in relation to lung cancer risk in a Chinese population. (2015 Aug 1)Yin JGene
23624123Effects of PPP1R13L and CD3EAP variants on lung cancer susceptibility among nonsmoking Chinese women. (2013 Jul 25)Yin JGene
24140460HapMap-based study identifies risk sub-region on chromosome 19q13.3 in relation to lung cancer among Chinese. (2013 Dec)Yin JCancer Epidemiol
26563375Association and interaction of NFKB1 rs28362491 insertion/deletion ATTG polymorphism and PPP1R13L and CD3EAP related to lung cancer risk in a Chinese population. (2016 Apr)Yin JTumour Biol